Elixiron Immunotherapeutics Inc.

banner banner_mb
Scroll
ABOUT US
Elixiron Immunotherapeutics specializes in precision immunotherapies for neuroinflammation, autoimmune diseases, and cancer. Leveraging deep expertise, the company has advanced two blockbuster candidates into clinical trials: EI-1071 (Enrupatinib) for Alzheimer’s, ALS, and Parkinson’s, and EI-001 (Indemakitug) for vitiligo and alopecia areata.

A recipient of the 2024 Taiwan BIO Award and 2025 National Innovation Award, Elixiron has twice secured "Part the Cloud" funding from Bill Gates and the Alzheimer’s Association to support EI-1071’s Phase I/II trials. With two successful patent licensing agreements already executed, Elixiron continues to validate its innovative pipeline through global partnerships and prestigious clinical backing.
MORE 閱讀更多
PIPELINE
slide Swipe left or right to view all content
  • 研發項目
    Name
  • 藥物形式
    Modality
  • 作用靶點
    Target
  • 適應症
    Indication
    • 藥物篩選
      Discovery
    • 臨床前研究
      Pre-Clinical
    • 臨床一期
      Phase I
    • 臨床二期
      Phase II
    • 臨床三期
      Phase III
  • 合作夥伴
    Partner
  • EI-001
  • Monoclonal Antibody
  • Interferon-Gamma
  • Vitiligo
    s arrow
  • EI-012
  • Monoclonal Antibody
  • CD36
  • Cancer
    s arrow
  • Pilatus Biosciences Inc. (US)
Precision Immunotherapy
Elixiron is transforming the treatment of immune-mediated diseases through precision immunotherapy, targeting the unique drivers of immune dysfunction in each condition. Leveraging cutting-edge research, we uncover intricate immune pathways and key biomarkers to develop therapies that address the root causes of disease. This innovative approach delivers more effective, targeted treatments, redefining care and offering new hope for individuals affected by immune-mediated conditions.
MORE 閱讀更多
mRNA Drug Development Platform
Elixiron's state-of-the-art mRNA drug development platform is revolutionizing biologic therapies by enabling in vivo protein expression and accelerating the transition from research to clinical application. Leveraging mRNA as a precise expression modality, this platform directs cells to produce therapeutic proteins within the body, overcoming traditional limitations and delivering highly targeted and efficient treatments. Its flexibility supports diverse applications, ranging from cancer immunotherapy to genetic modification, while dramatically reducing development time and costs, setting new standards in innovative patient care.
MORE 閱讀更多
s arrow
s arrow
BACK 返回
s arrow